<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04549870</url>
  </required_header>
  <id_info>
    <org_study_id>H-20013697</org_study_id>
    <nct_id>NCT04549870</nct_id>
  </id_info>
  <brief_title>Efficacy of Roflumilast in the Treatment of Psoriasis</brief_title>
  <acronym>PSORRO</acronym>
  <official_title>Efficacy of Roflumilast in the Treatment of Psoriasis - a Randomised Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bispebjerg Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bispebjerg Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Roflumilast (Daxas®), a selective, long-acting inhibitor of the enzyme phosphodiesterase-4&#xD;
      (PDE4), is used for severe chronic obstructive pulmonary disease. Recent research suggest&#xD;
      roflumilast is effective in treating psoriasis. The aim of this investigator-initiated trial&#xD;
      is to study the efficacy of oral roflumilast in patients with plaque psoriasis. This has not&#xD;
      previously been done.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Aim: To investigate the efficacy of roflumilast in the treatment of psoriasis.&#xD;
&#xD;
      Design: Multicentre, double-blinded, randomised, placebo-controlled, clinical trial.&#xD;
&#xD;
      Participants: Patients ≥18 years with plaque psoriasis.&#xD;
&#xD;
      Method: Twelve weeks treatment with either roflumilast or placebo tablets. Both groups&#xD;
      continue for an additional 12 weeks open-label treatment.&#xD;
&#xD;
      Primary endpoint: Proportion of patients achieving at least 75% reduction from baseline&#xD;
      psoriasis area and severity index (PASI75) at week 12.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2021</start_date>
  <completion_date type="Anticipated">April 2022</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PASI75</measure>
    <time_frame>12 weeks</time_frame>
    <description>Proportion of patients achieving at least 75% reduction from baseline psoriasis area and severity index (PASI75) at week 12. PASI is a measure of psoriatic disease severity.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Psoriasis</condition>
  <arm_group>
    <arm_group_label>Roflumilast</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Roflumilast 500 microgram daily (capsule)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (capsule)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Roflumilast</intervention_name>
    <description>Treatment according to national roflumilast guidelines</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Roflumilast</arm_group_label>
    <other_name>Daxas</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥18 years&#xD;
&#xD;
          -  Chronic stable plaque psoriasis (min duration 6 months)&#xD;
&#xD;
          -  PASI &gt;8&#xD;
&#xD;
          -  Body mass index (BMI) &gt; 20 kg/m2&#xD;
&#xD;
          -  Candidate for systemic treatment of psoriasis&#xD;
&#xD;
          -  Negative pregnancy test (only women)&#xD;
&#xD;
          -  Safe anticonception during entire study and at least 1 week after end of treatment (~5&#xD;
             times plasma half-life of roflumilast) (only applying for fertile women)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Severe immunological disease, e.g. HIV, systemic lupus, and systemic sclerosis&#xD;
&#xD;
          -  Current tuberculosis&#xD;
&#xD;
          -  Current viral hepatitis&#xD;
&#xD;
          -  Heart failure (NYHA III-IV)&#xD;
&#xD;
          -  Moderate or severe liver failure (Child-Pugh B-C)&#xD;
&#xD;
          -  Current or former malignancy (basal cell carcinoma excluded)&#xD;
&#xD;
          -  Current or former depression with suicidal ideation&#xD;
&#xD;
          -  Topical therapy for psoriasis during within 2 of randomization or during study&#xD;
&#xD;
          -  Systemic therapy for psoriasis or psoriatic arthritis within 4 weeks of randomization&#xD;
             or during study&#xD;
&#xD;
          -  Treatment with theophylline, phenobarbital, carbamazepine, or phenytoin&#xD;
&#xD;
          -  Confirmed pregnancy&#xD;
&#xD;
          -  Planned pregnancy within 6 months&#xD;
&#xD;
          -  Breast feeding&#xD;
&#xD;
          -  Blood donation during study&#xD;
&#xD;
          -  Inability to complete study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alexander Egeberg, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Bispebjerg Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alexander Egeberg, MD, PhD</last_name>
    <phone>+4524215421</phone>
    <email>alexander.egeberg@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mette Gyldenløve</last_name>
    <phone>+4529933935</phone>
    <email>mette.gyldenloeve@regionh.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Bispebjerg Hospital</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexander Egeberg</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>September 8, 2020</study_first_submitted>
  <study_first_submitted_qc>September 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 16, 2020</study_first_posted>
  <last_update_submitted>February 16, 2021</last_update_submitted>
  <last_update_submitted_qc>February 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Bispebjerg Hospital</investigator_affiliation>
    <investigator_full_name>Mette Gyldenløve</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

